Clinical profile, treatment, and outcomes of patients with mantle cell lymphoma treated in a tertiary care center in South India
| Autor: | L. Dasappa, Lakshmaiah Chinnagiriyappa Kuntegowdanahalli, Rudresha Antapura Halleshappa, Suparna Ajit Rao, Rajeev Lakkavalli Krishnappa, Linu Abraham Jacob, Sunny Garg, K N Lokesh, Suresh Babu Mallekavu Chikkadasappa, Govinda Babu Kanakasetty, Premalata Chennagiri Srinivasamurthy |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Cyclophosphamide business.industry General Medicine CHOP medicine.disease Surgery Extranodal Disease International Prognostic Index medicine.anatomical_structure hemic and lymphatic diseases Internal medicine medicine Prednisolone Mantle cell lymphoma Rituximab Bone marrow business medicine.drug |
| Zdroj: | Clinical Cancer Investigation Journal. 5:369 |
| ISSN: | 2278-0513 |
| DOI: | 10.4103/2278-0513.197863 |
| Popis: | Introduction: Mantle cell lymphoma has an aggressive course, with unfavorable outcomes. Subjects and Methods : A retrospective analysis was undertaken and 77 cases were identified between 2009 and 2014. Results : Median age was 55 years with a male to female ratio of 6:1. Patients with pure nodal disease at presentation were fewer than with extranodal disease (53.2%). Most common extranodal site was bone marrow. A number of patients with low-, low-intermediate, high-intermediate, and high-risk International Prognostic Index (IPI) scores were 6, 24, 22, and 25. Treatment consisted of cyclophosphamide,hydroxydaunorubicin, oncovin, prednisolone (CHOP) or R-CHOP regimens. Median survival was 21 months. Median overall survival with early and advanced disease was 31 and 18 months ( P = 0.02). Patients who received R-CHOP survived better than those given CHOP, 30 and 16 months ( P = 0.0002). There was no difference in survival with respect to age, gender, extranodal, or bone marrow involvement. Conclusions : Most patients presented with extranodal disease, advanced stage, and high IPI. Although rituximab has improved survival, intensive chemotherapy would be required to improve survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|